Indonesian Political, Business & Finance News

Doctor reveals obstacles in lung cancer treatment in Indonesia

| Source: Antara (Indonesian) Translated from Indonesian | Health Policy
Doctor reveals obstacles in lung cancer treatment in Indonesia
Image: Antara (Indonesian)

Jakarta (ANTARA) - Lung specialist and pulmonary oncology consultant, Prof. Dr. dr. Laksmi Wulandari, Sp.P (K), FISCM, FISR, has revealed several obstacles in the management of lung cancer in Indonesia.

“The challenges in managing lung cancer currently still involve aspects of promotion and prevention that have not yet functioned optimally and remain sporadic, resulting in the burden of treatment being more focused on the curative stage,” Laksmi stated in an official briefing in Jakarta on Thursday.

Laksmi noted that lung cancer management still faces various challenges, such as limited screening facilities, increasing air pollution, and uneven access to healthcare services.

According to her, Indonesia already possesses guidelines based on the NCCN (National Comprehensive Cancer Network) standards, which recommend annual lung cancer screening using Low-Dose CT Thorax (LDCT), particularly for high-risk groups. However, to date, implementation in Indonesia has not been widespread.

This can delay patient treatment, even though accurate diagnostic results are vital for doctors to determine the appropriate therapy for a patient’s specific cancer type.

Therapy options for lung cancer continue to evolve, ranging from radiotherapy, chemotherapy, and targeted therapy to immunotherapy. However, not all medical innovations are widely accessible or covered by the government.

In Japan, Singapore, Malaysia, South Korea, Taiwan, and China, third-generation targeted therapy has been integrated into health financing schemes. Meanwhile, in Indonesia, BPJS Kesehatan coverage is currently limited to first and second-generation targeted therapies, meaning access to third-generation targeted therapy is not yet widely available to lung cancer patients.

Consequently, she recommended that the government be more adaptive in providing access to medicines for lung cancer patients. Access to the correct therapy, provided at the right time, plays a crucial role in determining patient outcomes.

Furthermore, promotional efforts need to focus on massive, well-organised education involving frontline healthcare workers who interact directly with the community, such as community health centres (Puskesmas) and primary healthcare facilities.

Advocacy Coordinator for BPJS Watch, Timboel Siregar, added that healthcare services are a constitutional right for all Indonesian citizens.

Access to medicines, medical devices, and high-quality healthcare facilities that keep pace with modern developments should be available to the entire population.

Based on GLOBOCAN 2022 data, approximately 2.4 million new lung cancer cases were recorded worldwide in 2022, accounting for 12.4 per cent of all cancer cases and contributing 18.7 per cent to total cancer deaths.

In Indonesia, lung cancer ranks as the second most common new cancer case after breast cancer and is the leading cause of cancer-related deaths, accounting for 14.1 per cent of deaths. Meanwhile, the number of cases among women continues to rise, with 9,797 new cases recorded in 2022.

More from 2 July 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/doctor-reveals-obstacles-in-lung-cancer-treatment-in-indonesia-1782986141)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5632297/dokter-beberkan-kendala-penanganan-kanker-paru-di-indonesia), translated from Indonesian
Print